Cellbion
Financials
Valuation Metrics
Cellbion's Market Cap is ₩1551B. At end of 2025 it was ₩3046B. Ranked #952 of 2,410 in KR market (top 40%), #460 of 1,631 on KOSDAQ (top 28%), #111 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 48%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 155.12B KRW | KR#952/2,410 Sec#111/231 |
| Revenue | 2.15B KRW | KR#2,371/2,410 Sec#214/231 |
| Net Income | 7.75B KRW | KR#1,050/2,410 Sec#66/231 |
| Total Assets | 83.32B KRW | KR#1,908/2,410 Sec#155/231 |
| Net Assets | 36.13B KRW | KR#2,108/2,410 Sec#185/231 |
| Employees | 43 | KR#2,100/2,410 Sec#193/231 |
| Value | ||
| P/E | 20.01x | KR#1,203/2,410 Sec#72/231 |
| P/B | 4.29x | KR#2,222/2,410 Sec#190/231 |
| P/S | 72.30x | KR#2,377/2,410 Sec#207/231 |
| FCF Yield | -4.52% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | 21.45% | KR#152/2,410 Sec#12/231 |
| ROA | 9.30% | KR#323/2,410 Sec#25/231 |
| Op. Margin | -447.16% | KR#2,351/2,410 Sec#204/231 |
| Revenue Growth | -15.05% | KR#2,031/2,410 Sec#186/231 |
| Financial Health | ||
| Debt Ratio | 130.61% | KR#1,788/2,410 Sec#199/231 |
| Total Debt | 7.05B KRW | KR#1,712/2,410 Sec#158/231 |
| FCF | -7.02B KRW | KR#1,587/2,410 Sec#131/231 |
| Cash | 1.71B KRW | KR#2,263/2,410 Sec#215/231 |
| Current Ratio | 33.44x | KR#7/2,410 Sec#3/231 |
| Performance | ||
| 1Y Return | -25.34% | KR#1,328/2,410 Sec#98/231 |
| 1M Return | -17.78% | KR#1,692/2,410 Sec#169/231 |
| From 52W High | -71.52% | KR#2,109/2,410 Sec#183/231 |
| 1Y MDD | -73.67% | KR#2,104/2,410 Sec#184/231 |
| Trading | ||
| Volume | 8,949 shares | KR#1,701/2,410 Sec#174/231 |
| Trading Value | 106.5M KRW | KR#1,248/2,410 Sec#131/231 |
| Foreign Own. | 3.39% | KR#1,177/2,410 Sec#108/231 |
| Per Share | ||
| EPS | 601 KRW | KR#925/2,410 Sec#64/231 |
| BPS | 2,800 KRW | KR#1,912/2,410 Sec#147/231 |
Company Info
CellBion was established in 2010 with the aim of becoming a global leader in radiopharmaceuticals, and was listed on the KOSDAQ market in 2024. The company focuses on developing new anti-cancer drugs for precision medicine and targeted therapy, with Lu-177-DGUL currently under development. It produces generic specialty pharmaceuticals and operates a contract development and manufacturing organization (CDMO) business through its GMP-certified injectable vial manufacturing facility. CellBion delivers patient-specific precision anti-cancer therapy for PSMA protein-expressing prostate cancer, improving patient quality of life and advancing medical care. CellBion is headquartered in Jongno-gu, Seoul.